Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
50% Enrollment Reached in Imetelstat Trial for MDS
source: pixabay.com

50% Enrollment Reached in Imetelstat Trial for MDS

Since its conception, biopharmaceutical company Geron Corporation ("Geron") has worked to develop first-in-class therapies for hematologic myeloid malignancies. More recently, Geron began evaluating imetelstat for patients with lower risk myelodysplastic syndromes…

Continue Reading 50% Enrollment Reached in Imetelstat Trial for MDS
Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
source: pixabay.com

Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response

According to a story from Hematology Advisor, a recent study released in Scientific Reports indicates that gene expression has the potential to predict both primary resistance and treatment response in patients living…

Continue Reading Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS
source: pixabay.com

UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS

What are the best treatments and diagnostic approaches for blood disorders like aplastic anemia and myelodysplastic syndromes (MDS)? The UT Southwestern Medical Center is trying to streamline these options and…

Continue Reading UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS
Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
source: pixabay.com

Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment

Historically, clinical trials have played an immense role in collecting patient data, understanding disease progression, and crafting more targeted treatments. This is especially true in the oncology realm. But according…

Continue Reading Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
source: pixabay.com

September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness

September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…

Continue Reading September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
source: pixabay.com

2 TP53 Mutations Worsen Blood Cancer Severity, Says Study

Recently, the MDS Foundation announced that two TP53 gene mutations result in worse patient outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to their international and multi center study,…

Continue Reading 2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?
source: pixabay.com

Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?

By Lauren Taylor from In The Cloud Copy Onconova Therapeutics, Inc. is a biopharmaceutical company that works to develop new drugs to treat cancer, primarily focusing on myelodysplastic syndromes. Myelodysplastic…

Continue Reading Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?
Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy
source: pixabay.com

Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy

According to a story from GlobeNewswire, the biopharmaceutical company Onconova Therapeutics, Inc. has recently published results from a phase 1 clinical trial that was sponsored by the company. This trial…

Continue Reading Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy
$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
source: pixabay.com

$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments

  After forty years of research to counter or cure acute myeloid leukemia and other blood cancers, a few years ago the medical community exploded with eight new cancer drugs.…

Continue Reading $6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
source: pixabay.com

International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers

  COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…

Continue Reading International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
source: pixabay.com

New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…

Continue Reading New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
source: pixabay.com

Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth

Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…

Continue Reading Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes
source: pixabay.com

Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes

A recent study published in Blood Cancer Journal has established a new method for effectively predicting survival outcomes for patients with low-risk myelodysplastic syndromes (MDS). The method is known as the…

Continue Reading Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes